Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD20 expression
i
Other names:
CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
494216
Related biomarkers:
Expression
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
CD20 expression
Non-Hodgkin’s Lymphoma
CD20 expression
Non-Hodgkin’s Lymphoma
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
CD20 expression
Chronic Lymphocytic Leukemia
CD20 expression
Chronic Lymphocytic Leukemia
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
rituximab-arrx
Sensitive: A1 - Approval
rituximab-arrx
Sensitive
:
A1
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
CD20 expression
Childhood B Acute Lymphoblastic Leukemia
rituximab + bortezomib
Sensitive: C3 – Early Trials
rituximab + bortezomib
Sensitive
:
C3
rituximab + bortezomib
Sensitive: C3 – Early Trials
rituximab + bortezomib
Sensitive
:
C3
CD20 expression
B Acute Lymphoblastic Leukemia
CD20 expression
B Acute Lymphoblastic Leukemia
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
rituximab
Sensitive: C3 – Early Trials
rituximab
Sensitive
:
C3
CD20 expression
Non-Hodgkin’s Lymphoma
CD20 expression
Non-Hodgkin’s Lymphoma
REGN1979
Resistant: C3 – Early Trials
REGN1979
Resistant
:
C3
REGN1979
Resistant: C3 – Early Trials
REGN1979
Resistant
:
C3
CD20 expression
Lymphoma
CD20 expression
Lymphoma
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
daratumumab + NKTR-255
Sensitive: C3 – Early Trials
daratumumab + NKTR-255
Sensitive
:
C3
CD20 expression
Lymphoma
CD20 expression
Lymphoma
ADI-001
Sensitive: C3 – Early Trials
ADI-001
Sensitive
:
C3
ADI-001
Sensitive: C3 – Early Trials
ADI-001
Sensitive
:
C3
CD20 expression
Lymphoma
CD20 expression
Lymphoma
NKTR-255 + Ritucad (rituximab biosimilar)
Sensitive: D – Preclinical
NKTR-255 + Ritucad (rituximab biosimilar)
Sensitive
:
D
NKTR-255 + Ritucad (rituximab biosimilar)
Sensitive: D – Preclinical
NKTR-255 + Ritucad (rituximab biosimilar)
Sensitive
:
D
CD20 expression
Non-Hodgkin’s Lymphoma
CD20 expression
Non-Hodgkin’s Lymphoma
lenalidomide + GEN-3013
Sensitive: D – Preclinical
lenalidomide + GEN-3013
Sensitive
:
D
lenalidomide + GEN-3013
Sensitive: D – Preclinical
lenalidomide + GEN-3013
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login